Atrium Health's Levine Cancer Institute - Charlotte (Main) Myeloma Trials

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Verified

A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma

DREAMM9

View Trial

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

DRAMMATIC

View Trial

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide ...

CARTITUDE-6

View Trial

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

MAJESTEC-7

View Trial

Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma

LINKER-MM4

View Trial

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

CHAAMP (CHARLOTTE AFRICAN AMERICAN MGUS PROJECT)

View Trial

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, ...

MONUMENTAL-3

View Trial

Verified

A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/...

LINKER-MM3

View Trial

Verified

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma

CARTITUDE-2

View Trial

Verified

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multipl...

KARMMA-2

View Trial

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

DRAMMATIC

View Trial

Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel

NIVOLUMAB POST TREATMENT WITH IDE-CEL

View Trial

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma

IMMAGINE-1

View Trial

Myeloma-Developing Regimens Using Genomics

MYDRUG

View Trial

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previ...

JNJ-79635322

View Trial

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

CHAAMP (CHARLOTTE AFRICAN AMERICAN MGUS PROJECT)

View Trial

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, ...

MONUMENTAL-3

View Trial

Verified

A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/...

LINKER-MM3

View Trial

Verified

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma

CARTITUDE-2

View Trial

Verified

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multipl...

KARMMA-2

View Trial

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

DRAMMATIC

View Trial

Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel

NIVOLUMAB POST TREATMENT WITH IDE-CEL

View Trial

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma

IMMAGINE-1

View Trial

Myeloma-Developing Regimens Using Genomics

MYDRUG

View Trial

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previ...

JNJ-79635322

View Trial

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Mye...

CAMMOUFLAGE

View Trial

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

CHAAMP (CHARLOTTE AFRICAN AMERICAN MGUS PROJECT)

View Trial

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

AMYLOIDOSIS SCREENING

View Trial

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

CHAAMP (CHARLOTTE AFRICAN AMERICAN MGUS PROJECT)

View Trial

Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

CHAAMP (CHARLOTTE AFRICAN AMERICAN MGUS PROJECT)

View Trial